Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company focuses on developing NX-1207, a treatment for benign prostatic hyperplasia (BPH) which is in Phase III trials in the United States. The Company has research and development (R&D) pipeline of products in development for the treatment of conditions and diseases such as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer’s disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. Nymox has a number of diagnostic markers and technologies, including a patented platform for point-of-care testing, and has tests utilizing these technologies in the early stages of development. Nymox also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. Nymox has two subsidiaries: Nymox Corporation and Serex, Inc.